GoodRx Announces Preliminary Fourth Quarter and Full Year 2023 Results and Early Expectations for First Quarter and Full Year 2024

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings, today provided preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Revenue1,2 and Adjusted Revenue1,2 expected to be in the range of $195 million to $197 million Adjusted EBITDA Margin2,3 expected to be in the upper end of previous guidance range provided on November 9, 2023 ...